Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody

Jun Amano, Naoko Masuyama, Yuko Hirota, Yoshitaka Tanaka, Yuriko Igawa, Rie Shiokawa, Taichi Okutani, Takashi Miyayama, Masahiko Nanami, Masaki Ishigai

研究成果: ジャーナルへの寄稿記事

11 引用 (Scopus)

抄録

Anti-HM1.24 monoclonal antibody (AHM) is a humanized anti-HM1.24 monoclonal antibody that binds to the HM1.24 antigen, a protein that is highly expressed in multiple myeloma cells. The pharmacokinetics of AHM was determined in experiments in which AHM was administered intravenously to cynomolgus monkeys. The area under the plasma concentration-time curve increased by more than the dose ratio between 2 and 20 mg/kg, and nonlinear pharmacokinetics was observed. The elimination half-life of AHM from the plasma was 7.56 h at 2 mg/kg and 28.6 h at 20 mg/kg, which was shorter than that observed for other therapeutic humanized monoclonal antibodies, such as trastuzumab and bevacizumab. Although antibodies to AHM were detected in all monkeys on or after 10 days of administration, there was a temporal disassociation between the rapid elimination of AHM and the appearance of anti-AHM antibodies. HM1.24 antigen-dependent internalization and intracellular metabolism of AHM were investigated in peripheral blood mononuclear, KPMM2, and U937 cells. In all cases, AHM was rapidly internalized from the cell surface; this internalization was significantly prevented by phenylarsine oxide in KPMM2 cells, an inhibitor of receptor-mediated endocytosis, and the internalized AHM was subsequently degraded within the cells. Furthermore, immunofluorescence microscopy revealed that the internalized AHM is delivered to and degraded in late endosomes/lysosomes. Taken together, our results suggest that the rapid elimination of AHM from plasma in monkey is due to HM1.24 antigen-dependent internalization followed by delivery to the lysosomes.

元の言語英語
ページ(範囲)2339-2346
ページ数8
ジャーナルDrug Metabolism and Disposition
38
発行部数12
DOI
出版物ステータス出版済み - 12 1 2010

Fingerprint

Monoclonal Antibodies
Antigens
Lysosomes
Haplorhini
Pharmacokinetics
Antibodies, Monoclonal, Humanized
U937 Cells
Macaca fascicularis
Endosomes
Endocytosis
Multiple Myeloma
Fluorescence Microscopy
Half-Life
Anti-Idiotypic Antibodies
Antibodies

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

これを引用

Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody. / Amano, Jun; Masuyama, Naoko; Hirota, Yuko; Tanaka, Yoshitaka; Igawa, Yuriko; Shiokawa, Rie; Okutani, Taichi; Miyayama, Takashi; Nanami, Masahiko; Ishigai, Masaki.

:: Drug Metabolism and Disposition, 巻 38, 番号 12, 01.12.2010, p. 2339-2346.

研究成果: ジャーナルへの寄稿記事

Amano, Jun ; Masuyama, Naoko ; Hirota, Yuko ; Tanaka, Yoshitaka ; Igawa, Yuriko ; Shiokawa, Rie ; Okutani, Taichi ; Miyayama, Takashi ; Nanami, Masahiko ; Ishigai, Masaki. / Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody. :: Drug Metabolism and Disposition. 2010 ; 巻 38, 番号 12. pp. 2339-2346.
@article{ab5698d55c63492a9395dc05d03a933d,
title = "Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody",
abstract = "Anti-HM1.24 monoclonal antibody (AHM) is a humanized anti-HM1.24 monoclonal antibody that binds to the HM1.24 antigen, a protein that is highly expressed in multiple myeloma cells. The pharmacokinetics of AHM was determined in experiments in which AHM was administered intravenously to cynomolgus monkeys. The area under the plasma concentration-time curve increased by more than the dose ratio between 2 and 20 mg/kg, and nonlinear pharmacokinetics was observed. The elimination half-life of AHM from the plasma was 7.56 h at 2 mg/kg and 28.6 h at 20 mg/kg, which was shorter than that observed for other therapeutic humanized monoclonal antibodies, such as trastuzumab and bevacizumab. Although antibodies to AHM were detected in all monkeys on or after 10 days of administration, there was a temporal disassociation between the rapid elimination of AHM and the appearance of anti-AHM antibodies. HM1.24 antigen-dependent internalization and intracellular metabolism of AHM were investigated in peripheral blood mononuclear, KPMM2, and U937 cells. In all cases, AHM was rapidly internalized from the cell surface; this internalization was significantly prevented by phenylarsine oxide in KPMM2 cells, an inhibitor of receptor-mediated endocytosis, and the internalized AHM was subsequently degraded within the cells. Furthermore, immunofluorescence microscopy revealed that the internalized AHM is delivered to and degraded in late endosomes/lysosomes. Taken together, our results suggest that the rapid elimination of AHM from plasma in monkey is due to HM1.24 antigen-dependent internalization followed by delivery to the lysosomes.",
author = "Jun Amano and Naoko Masuyama and Yuko Hirota and Yoshitaka Tanaka and Yuriko Igawa and Rie Shiokawa and Taichi Okutani and Takashi Miyayama and Masahiko Nanami and Masaki Ishigai",
year = "2010",
month = "12",
day = "1",
doi = "10.1124/dmd.110.035709",
language = "English",
volume = "38",
pages = "2339--2346",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "12",

}

TY - JOUR

T1 - Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody

AU - Amano, Jun

AU - Masuyama, Naoko

AU - Hirota, Yuko

AU - Tanaka, Yoshitaka

AU - Igawa, Yuriko

AU - Shiokawa, Rie

AU - Okutani, Taichi

AU - Miyayama, Takashi

AU - Nanami, Masahiko

AU - Ishigai, Masaki

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Anti-HM1.24 monoclonal antibody (AHM) is a humanized anti-HM1.24 monoclonal antibody that binds to the HM1.24 antigen, a protein that is highly expressed in multiple myeloma cells. The pharmacokinetics of AHM was determined in experiments in which AHM was administered intravenously to cynomolgus monkeys. The area under the plasma concentration-time curve increased by more than the dose ratio between 2 and 20 mg/kg, and nonlinear pharmacokinetics was observed. The elimination half-life of AHM from the plasma was 7.56 h at 2 mg/kg and 28.6 h at 20 mg/kg, which was shorter than that observed for other therapeutic humanized monoclonal antibodies, such as trastuzumab and bevacizumab. Although antibodies to AHM were detected in all monkeys on or after 10 days of administration, there was a temporal disassociation between the rapid elimination of AHM and the appearance of anti-AHM antibodies. HM1.24 antigen-dependent internalization and intracellular metabolism of AHM were investigated in peripheral blood mononuclear, KPMM2, and U937 cells. In all cases, AHM was rapidly internalized from the cell surface; this internalization was significantly prevented by phenylarsine oxide in KPMM2 cells, an inhibitor of receptor-mediated endocytosis, and the internalized AHM was subsequently degraded within the cells. Furthermore, immunofluorescence microscopy revealed that the internalized AHM is delivered to and degraded in late endosomes/lysosomes. Taken together, our results suggest that the rapid elimination of AHM from plasma in monkey is due to HM1.24 antigen-dependent internalization followed by delivery to the lysosomes.

AB - Anti-HM1.24 monoclonal antibody (AHM) is a humanized anti-HM1.24 monoclonal antibody that binds to the HM1.24 antigen, a protein that is highly expressed in multiple myeloma cells. The pharmacokinetics of AHM was determined in experiments in which AHM was administered intravenously to cynomolgus monkeys. The area under the plasma concentration-time curve increased by more than the dose ratio between 2 and 20 mg/kg, and nonlinear pharmacokinetics was observed. The elimination half-life of AHM from the plasma was 7.56 h at 2 mg/kg and 28.6 h at 20 mg/kg, which was shorter than that observed for other therapeutic humanized monoclonal antibodies, such as trastuzumab and bevacizumab. Although antibodies to AHM were detected in all monkeys on or after 10 days of administration, there was a temporal disassociation between the rapid elimination of AHM and the appearance of anti-AHM antibodies. HM1.24 antigen-dependent internalization and intracellular metabolism of AHM were investigated in peripheral blood mononuclear, KPMM2, and U937 cells. In all cases, AHM was rapidly internalized from the cell surface; this internalization was significantly prevented by phenylarsine oxide in KPMM2 cells, an inhibitor of receptor-mediated endocytosis, and the internalized AHM was subsequently degraded within the cells. Furthermore, immunofluorescence microscopy revealed that the internalized AHM is delivered to and degraded in late endosomes/lysosomes. Taken together, our results suggest that the rapid elimination of AHM from plasma in monkey is due to HM1.24 antigen-dependent internalization followed by delivery to the lysosomes.

UR - http://www.scopus.com/inward/record.url?scp=78649620561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649620561&partnerID=8YFLogxK

U2 - 10.1124/dmd.110.035709

DO - 10.1124/dmd.110.035709

M3 - Article

C2 - 20823293

AN - SCOPUS:78649620561

VL - 38

SP - 2339

EP - 2346

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 12

ER -